MDX-010 (tremelimumab)

tremelimumab · Bristol-Myers Squibb

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for MDX-010 (tremelimumab), covering 2011-06-23 to 2014-08-28. Get the full timeline:

Most recent: Clinical Trial Update: Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer [Phase 1, Phase 2]